1 completed, 1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow FLT3-ITD: new trials by email Literature Review of FLT3-ITD trials Research Report on FLT3-ITD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE Refractory AML, Relapsed Adult AML | Completed | French Innovative Leukemia Organisation | 177 | 2021-07-05 | 2023-05-24 |
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Azacitidine (1) · cc-486 (1) · gilteritinib (1)
French Innovative Leukemia Organisation (2)
France (2)